Literature DB >> 19015638

ILEI requires oncogenic Ras for the epithelial to mesenchymal transition of hepatocytes and liver carcinoma progression.

C Lahsnig1, M Mikula, M Petz, G Zulehner, D Schneller, F van Zijl, H Huber, A Csiszar, H Beug, W Mikulits.   

Abstract

In human hepatocellular carcinoma (HCC), epithelial to mesenchymal transition (EMT) correlates with aggressiveness of tumors and poor survival. We employed a model of EMT based on immortalized p19(ARF) null hepatocytes (MIM), which display tumor growth upon expression of oncogenic Ras and undergo EMT through the synergism of Ras and transforming growth factor (TGF)-beta. Here, we show that the interleukin-related protein interleukin-like EMT inducer (ILEI), a novel EMT-, tumor- and metastasis-inducing protein, cooperates with oncogenic Ras to cause TGF-beta-independent EMT. Ras-transformed MIM hepatocytes overexpressing ILEI showed cytoplasmic E-cadherin, loss of ZO-1 and induction of alpha-smooth muscle actin as well as platelet-derived growth factor (PDGF)/PDGF-R isoforms. As shown by dominant-negative PDGF-R expression in these cells, ILEI-induced PDGF signaling was required for enhanced cell migration, nuclear accumulation of beta-catenin, nuclear pY-Stat3 and accelerated growth of lung metastases. In MIM hepatocytes expressing the Ras mutant V12-C40, ILEI collaborated with PI3K signaling resulting in tumor formation without EMT. Clinically, human HCC samples showed granular or cytoplasmic localization of ILEI correlating with well and poorly differentiated tumors, respectively. In conclusion, these data indicate that ILEI requires cooperation with oncogenic Ras to govern hepatocellular EMT through mechanisms involving PDGF-R/beta-catenin and PDGF-R/Stat3 signaling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19015638      PMCID: PMC2900603          DOI: 10.1038/onc.2008.418

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  41 in total

Review 1.  Dysregulation of growth factor signaling in human hepatocellular carcinoma.

Authors:  K Breuhahn; T Longerich; P Schirmacher
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

2.  Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition.

Authors:  Terence K Lee; Kwan Man; Ronnie T P Poon; Chung Mau Lo; Anthony P Yuen; Irene O Ng; Kevin T Ng; Warren Leonard; Sheung Tat Fan
Journal:  Cancer Res       Date:  2006-10-15       Impact factor: 12.701

3.  Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis.

Authors:  Hisanobu Ogata; Takashi Kobayashi; Takatoshi Chinen; Hiromi Takaki; Takahito Sanada; Yasumasa Minoda; Keiko Koga; Giichi Takaesu; Yoshihiko Maehara; Mitsuo Iida; Akihiko Yoshimura
Journal:  Gastroenterology       Date:  2006-07       Impact factor: 22.682

4.  ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells.

Authors:  Thomas Waerner; Memetcan Alacakaptan; Ido Tamir; Rupert Oberauer; Annamaria Gal; Thomas Brabletz; Martin Schreiber; Martin Jechlinger; Hartmut Beug
Journal:  Cancer Cell       Date:  2006-09       Impact factor: 31.743

5.  Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.

Authors:  R Garcia; T L Bowman; G Niu; H Yu; S Minton; C A Muro-Cacho; C E Cox; R Falcone; R Fairclough; S Parsons; A Laudano; A Gazit; A Levitzki; A Kraker; R Jove
Journal:  Oncogene       Date:  2001-05-03       Impact factor: 9.867

6.  A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes.

Authors:  J Gotzmann; A N M Fischer; M Zojer; M Mikula; V Proell; H Huber; M Jechlinger; T Waerner; A Weith; H Beug; W Mikulits
Journal:  Oncogene       Date:  2006-05-25       Impact factor: 9.867

7.  Autocrine PDGFR signaling promotes mammary cancer metastasis.

Authors:  Martin Jechlinger; Andreas Sommer; Richard Moriggl; Peter Seither; Norbert Kraut; Paola Capodiecci; Michael Donovan; Carlos Cordon-Cardo; Hartmut Beug; Stefan Grünert
Journal:  J Clin Invest       Date:  2006-06       Impact factor: 14.808

8.  Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.

Authors:  Diego F Calvisi; Sara Ladu; Alexis Gorden; Miriam Farina; Elizabeth A Conner; Ju-Seog Lee; Valentina M Factor; Snorri S Thorgeirsson
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

9.  NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma.

Authors:  Doris Macheiner; Gerwin Heller; Sonja Kappel; Christoph Bichler; Stefan Stättner; Barbara Ziegler; Daniela Kandioler; Fritz Wrba; Rolf Schulte-Hermann; Sabine Zöchbauer-Müller; Bettina Grasl-Kraupp
Journal:  J Hepatol       Date:  2006-02-07       Impact factor: 25.083

10.  Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta1 production.

Authors:  H Ogata; T Chinen; T Yoshida; I Kinjyo; G Takaesu; H Shiraishi; M Iida; T Kobayashi; A Yoshimura
Journal:  Oncogene       Date:  2006-04-20       Impact factor: 9.867

View more
  38 in total

1.  IL-6 increases MMP-13 expression and motility in human chondrosarcoma cells.

Authors:  Chih-Hsin Tang; Cheng-Fong Chen; Wei-Ming Chen; Yi-Chin Fong
Journal:  J Biol Chem       Date:  2011-01-28       Impact factor: 5.157

2.  Epithelial-mesenchymal transitions and hepatocarcinogenesis.

Authors:  Janice Jou; Anna Mae Diehl
Journal:  J Clin Invest       Date:  2010-03-24       Impact factor: 14.808

3.  The interleukin-like epithelial-mesenchymal transition inducer ILEI exhibits a non-interleukin-like fold and is active as a domain-swapped dimer.

Authors:  Anna M Jansson; Agnes Csiszar; Joachim Maier; Ann-Christin Nyström; Elisabeth Ax; Patrik Johansson; Lovisa Holmberg Schiavone
Journal:  J Biol Chem       Date:  2017-07-27       Impact factor: 5.157

4.  Fam3c modulates osteogenic cell differentiation and affects bone volume and cortical bone mineral density.

Authors:  Jorma A Määttä; Ameya Bendre; Mervi Laanti; Kalman G Büki; Pia Rantakari; Päivi Tervola; Johanna Saarimäki; Matti Poutanen; Pirkko Härkönen; Kalervo Väänänen
Journal:  Bonekey Rep       Date:  2016-04-06

Review 5.  TGF-beta signaling in cancer: post-transcriptional regulation of EMT via hnRNP E1.

Authors:  Breege V Howley; Philip H Howe
Journal:  Cytokine       Date:  2018-02-01       Impact factor: 3.861

6.  Identification of secreted proteins that reflect autophagy dynamics within tumor cells.

Authors:  Adam A Kraya; Shengfu Piao; Xiaowei Xu; Gao Zhang; Meenhard Herlyn; Phyllis Gimotty; Beth Levine; Ravi K Amaravadi; David W Speicher
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

7.  Nuclear beta-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence.

Authors:  Gudrun Zulehner; Mario Mikula; Doris Schneller; Franziska van Zijl; Heidemarie Huber; Wolfgang Sieghart; Bettina Grasl-Kraupp; Thomas Waldhör; Markus Peck-Radosavljevic; Hartmut Beug; Wolfgang Mikulits
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

8.  PDGFRB promotes liver metastasis formation of mesenchymal-like colorectal tumor cells.

Authors:  Ernst J A Steller; Danielle A Raats; Jan Koster; Bert Rutten; Klaas M Govaert; Benjamin L Emmink; Nikol Snoeren; Sander R van Hooff; Frank C P Holstege; Coen Maas; Inne H M Borel Rinkes; Onno Kranenburg
Journal:  Neoplasia       Date:  2013-02       Impact factor: 5.715

9.  Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge.

Authors:  F van Zijl; M Mair; A Csiszar; D Schneller; G Zulehner; H Huber; R Eferl; H Beug; H Dolznig; W Mikulits
Journal:  Oncogene       Date:  2009-08-31       Impact factor: 9.867

10.  Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells.

Authors:  Haluk Yuzugullu; Khemais Benhaj; Nuri Ozturk; Serif Senturk; Emine Celik; Asli Toylu; Nilgun Tasdemir; Mustafa Yilmaz; Esra Erdal; Kamil Can Akcali; Nese Atabey; Mehmet Ozturk
Journal:  Mol Cancer       Date:  2009-10-22       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.